Skip to content

Decision

Union procedures for the authorisation and supervision of medicinal products for human use and rules governing the European Medicines Agency

Effect
Passed
Result
488 for · 67 against · 34 abstained roll call
Date
10 April 2024, 19:22–19:23
Kind
New EU law · 1st reading
More facts (8)
Margin
by an overwhelming majority
Dossier
2023-0131
Source
Committee report by Tiemo Wölken
Votes
40 votes · 6 roll calls · 5 amendments
Requested by
The Left (1 roll call) · ECR (5 split votes, 1 separate vote) · ID (1 roll call)
Final vote
166879
More

Result

The final vote and what it means for this kind of decision.

Final vote: 488 for, 67 against, 34 abstained (roll call).

Passed by an overwhelming majority.

Parliament adopted its position on the law.

Before the final vote, MEPs decided on 5 amendments (5 rejected) and 8 parts of the text voted on separately (1 adopted, 7 rejected).

Backed by Greens, S&D, Renew, EPP and ECR; opposed by The Left, Patriots and ESN.

Groups

Members counted in their current group: the view with groups at the date of the vote is not available right now.

Members’ votes by their current group. Majority: the most common position. Clear line: a position with at least two thirds of the group’s votes, otherwise Divided.
GroupForAgainstAbst.Majority lineClear lineBar
The LeftFor 5Against 6Abst. 1Majority line AgainstClear line Divided
GreensFor 27Against 1Abst. 0Majority line ForClear line For
S&DFor 57Against 1Abst. 0Majority line ForClear line For
RenewFor 38Against 0Abst. 0Majority line ForClear line For
EPPFor 75Against 1Abst. 1Majority line ForClear line For
ECRFor 15Against 10Abst. 0Majority line ForClear line Divided
PatriotsFor 6Against 15Abst. 5Majority line AgainstClear line Divided
ESNFor 0Against 4Abst. 0Majority line AgainstClear line Against
No groupFor 3Against 2Abst. 0Majority line ForClear line Divided

Voted against their group, 0

Members who voted otherwise than a clear line (at least two thirds of the votes cast) of their group — groups as of today: the view with groups at the date of the vote is not available right now.

Nobody voted against a clear line of their group.

Countries

The final vote by national delegation.

The breakdown by country is not available right now.

Members

Each member’s recorded position on the final roll call — groups as of today: the view with groups at the date of the vote is not available right now.

Show all 589 members

Debate speakers and how they voted

The debate speakers are not available right now.

All votes on this decision, 40

In voting order. Result: for–against–abstained (a show of hands has no count). Requested by: the groups that asked for a roll call, a split vote or a separate vote.
No.VoteRecordedResultRequested by
1Amendments by the committee responsible — put to the vote collectively Amendments by the committee responsible – put to the vote collectively Show of hands Adopted
2Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
3Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
Show the other 39 votesShow the other 37 votes
Votes on this decision, continued
No.VoteRecordedResultRequested by
2Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
3Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
Votes on this decision, continued
No.VoteRecordedResultRequested by
4Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
5Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
6Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
7Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
8Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
9Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
10Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
11Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Counted348 for, 222 against, 5 abstained Adopted
12Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
13Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
14Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
15Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
16Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
17Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
18Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
19Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
20Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
21Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
22Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
23Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
24Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
25Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
26Amendments by the committee responsible — separate vote Amendments by the committee responsible – separate vote Show of hands Adopted
27Separate vote on Article 30, paragraph 3 Show of hands Rejected
28Separate vote on Article 31, paragraph 1, introductory part Show of hands Rejected
29Separate vote on Article 31, paragraph 1, point b Show of hands Rejected
30Separate vote on Article 33, paragraph 2 Show of hands Rejected
31Separate vote on Article 33, paragraph 2 Show of hands Adopted
32Amendment 373 to Article 33, paragraph 3 A9-0141/2024 – Tiemo Wölken – Article 33, § 3 – Am 373 Roll call129 for, 459 against, 1 abstained RejectedRequested byroll call: ID
33Separate vote on Article 33, after paragraph 3 Show of hands Rejected
34Separate vote on Article 34, paragraph 1 Show of hands Rejected
35Separate vote on Article 35, paragraph 1, point a Show of hands Rejected
36Amendment 379, adding text after Article 40 A9-0141/2024 – Tiemo Wölken – After Article 40 – Am 379 Roll call156 for, 334 against, 98 abstained RejectedRequested byroll call: The Left
37Amendment 378 to Article 134, before paragraph 1 A9-0141/2024 – Tiemo Wölken – Article 134, before § 1 – Am 378 Roll call96 for, 450 against, 36 abstained RejectedRequested byroll call: The Left
38Amendment 377, adding text after recital 3 A9-0141/2024 – Tiemo Wölken – After recital 3 – Am 377 Roll call73 for, 504 against, 15 abstained RejectedRequested byroll call: The Left
39Amendment 368, adding text after recital 5 A9-0141/2024 – Tiemo Wölken – After recital 5 – Am 368 Roll call62 for, 443 against, 59 abstained RejectedRequested byroll call: ID
40Final vote A9-0141/2024 – Tiemo Wölken – Commission proposal Roll call488 for, 67 against, 34 abstained Adopted

Roll calls requested by The Left, ID · split votes by ECR (5) · separate votes by ECR.

Text

The text voted on.

Report A-9-2024-0141

AI: The text in short Written by AI from the official text — check the source

Parliament's amended version of the Commission proposal for a regulation on authorising and supervising human medicines and on the European Medicines Agency. It adds rules on medicine shortages, environmental risk assessment, antimicrobial incentives, orphan and paediatric medicines, transparency and regulatory sandboxes.

Read the text · Report a problem

Dossier

Where the dossier stands and its other decisions in plenary.

2023/0131(COD) · Ordinary legislative procedure

Laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) No 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No 1901/2006

Parliament’s committee approved the deal reached with the Council on 18 March 2026; the plenary vote on it is still to come.

Show the 6 steps of the dossier
  1. Referred to committee · 14 September 2023 (done)
  2. Committee work · Report adopted 19 March 2024 (done)
  3. Tabled for plenary · 21 March 2024 (done)
  4. Plenary vote · Adopted 10 April 2024 (done)
  5. Negotiations with the Council · Deal approved in committee 18 March 2026 (current stage)
  6. Published as law (to come)

Lead committee: ENVI · Rapporteur: Tiemo WÖLKEN (S&D)

Connections

What this decision touches: the procedural chain, the same text, running issues, votes that split the chamber the same way.

No connections found for this decision.

Sources & citation

Where the facts on this page come from, and how to cite it.

Retrieved
25 September 2026

Cite as

European Parliament (2024). “Union procedures for the authorisation and supervision of medicinal products for human use and rules governing the European Medicines Agency”. Decision, 10 April 2024. votingId 166879, document A-9-2024-0141, reference 2023-0131. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/decisions/2024-04-10/32 (retrieved 25 September 2026). Official sources: Roll-call votes, sitting of 10 April 2024 (European Parliament), https://www.europarl.europa.eu/doceo/document/PV-10-2024-04-10-RCV_EN.html; Results of votes, sitting of 10 April 2024 (European Parliament), https://www.europarl.europa.eu/doceo/document/PV-10-2024-04-10-VOT_EN.html. Data: EP Open Data API: decisions of the sitting MTG-PL-2024-04-10, https://data.europarl.europa.eu/api/v2/meetings/MTG-PL-2024-04-10/decisions?format=application%2Fld%2Bjson (CC BY 4.0).
BibTeX
@misc{epw-decision-2024-04-10-32,
  author = {{European Parliament}},
  title = {{Union procedures for the authorisation and supervision of medicinal products for human use and rules governing the European Medicines Agency}},
  year = {2024},
  date = {2024-04-10},
  howpublished = {\url{https://news.eu-parl.st-solutions.dev/decisions/2024-04-10/32}},
  url = {https://news.eu-parl.st-solutions.dev/decisions/2024-04-10/32},
  urldate = {2026-09-25},
  publisher = {EU Parl Watch Research},
  note = {Decision. votingId 166879, document A-9-2024-0141, reference 2023-0131. Official source: https://www.europarl.europa.eu/doceo/document/PV-10-2024-04-10-RCV\_EN.html, https://www.europarl.europa.eu/doceo/document/PV-10-2024-04-10-VOT\_EN.html. Data: EP Open Data API: decisions of the sitting MTG-PL-2024-04-10 (CC BY 4.0)}
}